GLyPharma was a private biopharmaceutical company created by CTI LSF and was based in Montreal, Canada. The company developed a long-acting GLP-2 receptor agonist for the treatment of rare gastrointestinal disorders, including short bowel syndrome. In 2018, GLyPharma was acquired by Therachon for $55M USD cash and shares in Therachon. Therachon was acquired by Pfizer for $810M USD a year later.
Short bowel syndrome
CTI LSF I
Lead
Director
September 13, 2012
GLyPharma acquired by Therachon for $55M USD + shares; Therachon later acquired by Pfizer for $810M USD
Seed
GLyPhama was created based on a deprioritized and highly de-risked asset from Ferring with best-in-class potential for treating short bowl syndrome
